EGFR and prostate carcinoma: The occurrence of the epithelial-to-mesenchymal transition (i.e., the acquisition of mesenchymal traits [87]) as a possible protective response have been observed in prostate cancer cells upon treatment with a NDI derivative able to cause the structural transition towards a G4 conformation of epidermal growth factor receptor (EGFR) gene promoter and the consequent marked reduction in EGFR protein amounts [93].